The Zhitong Finance App learned that after a sharp drop of nearly 16% yesterday, Lizhu Pharmaceutical (01513) continued to drop by more than 3%, hitting a two-year low of HK$20.18 in the intraday period. As of press release, it decreased by 3.33% to HK$20.3, with a turnover of HK$70.49 million.
According to the news, Livzon Pharmaceutical recently announced its 2026 interim results. In the first half of the year, it achieved operating income of about 5 billion yuan, a decrease of 20.28% over the previous year; net profit attributable to shareholders of the parent company was 932 million yuan, a decrease of 27.23% over the previous year. Looking at the second quarter alone, the company achieved operating income of 2.13 billion yuan, a year-on-year decrease of 31.1%; net profit to mother was 355 million yuan, a year-on-year decrease of 44.9%.
In terms of specific business, the sharp decline in the performance of chemical preparations and traditional Chinese medicine formulations has become a major factor dragging down the company's overall revenue. During the reporting period, sales revenue from the chemical formulation business segment fell by 25.33%, mainly affected by medical insurance price cuts and national procurement; sales revenue from traditional Chinese medicine preparations and other business segments decreased by 34.83%. This is due to the decline in the incidence of influenza and respiratory diseases in the country in the first quarter of this year, which led to a decline in demand for related products.